Barrett's Oesophagus

1. Overview

Barrett's Oesophagus (BO) is a pre-malignant condition characterized by the replacement of the normal stratified squamous epithelium of the distal oesophagus with metaplastic columnar epithelium containing goblet cells (intestinal metaplasia). [1]

It represents an adaptive response to chronic gastro-oesophageal reflux disease (GORD) and is the single most important precursor lesion for oesophageal adenocarcinoma (OAC), which has shown a dramatic increase in incidence over the past four decades in Western populations. [2]

Key Definitions

Barrett's Oesophagus requires:

1. Endoscopic evidence: Columnar-lined epithelium extending proximally from the gastro-oesophageal junction (GOJ)
2. Histological confirmation: Intestinal metaplasia with goblet cells on biopsy [3]

Note: The presence of goblet cells (intestinal metaplasia) is essential for diagnosis in most Western guidelines, though some international guidelines accept columnar metaplasia alone. [1,3]

---

2. Epidemiology

Prevalence

• General population: 1.6-2.0% in population-based studies [4]
• GORD patients: 10-15% of patients undergoing endoscopy for chronic reflux symptoms [5]
• Gender ratio: Male predominance (2-3:1 male to female) [4]
• Age: Peak diagnosis 55-65 years; rare under 30 years [4]

Geographic and Ethnic Variation

• Highest prevalence: Western Europe, North America, Australia
• Ethnic differences:
  • "White populations: 1.6-2.0%"
  • "Asian populations: 0.4-0.5%"
  • "African/Hispanic: Lower than white populations [4,5]"

Incidence Trends

The incidence of both Barrett's oesophagus and oesophageal adenocarcinoma has risen dramatically:

• 300-500% increase in OAC incidence in Western countries since 1970s [2]
• Barrett's oesophagus diagnosis has increased correspondingly, partly due to increased endoscopic surveillance [4]

Cancer Risk

• Annual progression rate to oesophageal adenocarcinoma:

  • "Non-dysplastic Barrett's: 0.2-0.5% per year [6]"
  • "Low-grade dysplasia (LGD): 0.5-1.0% per year [6]"
  • "High-grade dysplasia (HGD): 5-7% per year (without treatment) [6]"

• Lifetime risk: Approximately 5-10% of patients with Barrett's will develop adenocarcinoma [2]

Risk Factors

Protective factors:

• Helicobacter pylori infection (inverse association, possibly via reduced acid secretion) [5]
• Aspirin/NSAID use (under investigation for chemoprevention) [7]

---

3. Pathophysiology

3.1 Molecular Pathogenesis

┌─────────────────────────────────────────────────────────────────────────────┐
│              BARRETT'S CARCINOGENESIS SEQUENCE                              │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │              STEP 1: CHRONIC ACID/BILE EXPOSURE                     │   │
│   │  • Gastro-oesophageal reflux (acidic pH 1-2)                        │   │
│   │  • Duodeno-gastric reflux (bile acids, pancreatic enzymes)          │   │
│   │  • Chronic epithelial injury and inflammation                       │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │              STEP 2: METAPLASIA (Adaptive Response)                 │   │
│   │  • Squamous epithelium → Columnar epithelium                        │   │
│   │  • Activation of intestinal transcription factors (CDX2, CDX1)      │   │
│   │  • Development of goblet cells (MUC2 production)                    │   │
│   │  • "Salmon-pink" mucosa on endoscopy                                │   │
│   │  • PROTECTIVE adaptation (more resistant to acid)                   │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │              STEP 3: GENOMIC INSTABILITY                            │   │
│   │  • Continued inflammation → DNA damage                              │   │
│   │  • Loss of p53 tumor suppressor function                            │   │
│   │  • Chromosomal abnormalities (aneuploidy, LOH)                      │   │
│   │  • Microsatellite instability                                       │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │              STEP 4: DYSPLASIA (Pre-invasive neoplasia)             │   │
│   │  • Low-grade dysplasia (LGD): Mild cytological atypia               │   │
│   │  • High-grade dysplasia (HGD): Severe atypia, architectural changes │   │
│   │  • Accumulation of mutations (TP53, CDKN2A/p16, SMAD4)              │   │
│   │  • Clonal expansion of dysplastic cells                             │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │              STEP 5: INVASIVE ADENOCARCINOMA                        │   │
│   │  • Breach of basement membrane                                      │   │
│   │  • Invasion into submucosa → lymphovascular invasion                │   │
│   │  • Metastatic potential                                             │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

3.2 Cellular Origin

The cellular origin of Barrett's metaplasia remains debated. Leading theories include: [8]

1. Trans-differentiation: Direct conversion of squamous cells to columnar cells
2. Stem cell hypothesis: Activation of multipotent stem cells at the GOJ
3. Bone marrow-derived cells: Migration and differentiation of circulating progenitor cells (less favored)

Recent evidence suggests Barrett's epithelium likely arises from residual embryonic columnar cells or progenitor cells in the basal layer of the squamous epithelium or submucosal gland ducts. [8]

3.3 Key Molecular Alterations

3.4 Role of Inflammation

Chronic reflux-induced inflammation drives carcinogenesis through:

• Reactive oxygen species (ROS) causing DNA damage [8]
• Cytokine signaling (IL-6, IL-8, TNF-α) promoting cell proliferation
• NF-κB activation supporting survival of damaged cells
• COX-2 overexpression (target for chemoprevention strategies) [7]

---

4. Clinical Features

4.1 Symptoms

Barrett's oesophagus itself is asymptomatic. [1]

Patients present with symptoms of the underlying GORD:

Typical GORD symptoms:

• Heartburn (pyrosis): Retrosternal burning, worse after meals/lying flat
• Regurgitation: Acid/food reflux into mouth
• Dyspepsia: Epigastric discomfort, bloating

Atypical symptoms:

• Chronic cough
• Hoarseness
• Dental erosion
• Asthma-like symptoms (nocturnal wheeze)

4.2 Warning Symptoms ("Red Flags")

These suggest progression to dysplasia/carcinoma or complications:

4.3 Physical Examination

Usually unremarkable in uncomplicated Barrett's oesophagus.

Examine for:

• Obesity (BMI, waist circumference): Major risk factor [5]
• Epigastric tenderness: Suggests active gastritis/oesophagitis
• Supraclavicular lymphadenopathy (Virchow's node): Metastatic disease
• Hepatomegaly: Metastatic disease
• Cachexia: Advanced malignancy

---

5. Diagnosis

5.1 Gold Standard: Upper GI Endoscopy (OGD) with Biopsy

Barrett's oesophagus diagnosis requires BOTH: [3]

1. Endoscopic visualization of columnar-lined epithelium
2. Histological confirmation of intestinal metaplasia (goblet cells)

5.2 Endoscopic Appearance

Key features:

• "Salmon-pink" mucosa extending proximally from the gastro-oesophageal junction (GOJ)
• Tongues or circumferential segments of columnar epithelium in the tubular oesophagus
• Displaced Z-line (squamo-columnar junction) proximal to the GOJ

Normal anatomy:

• Z-line should coincide with GOJ (top of gastric folds)
• Oesophageal mucosa: pale, glossy (squamous)
• Gastric mucosa: salmon-pink (columnar)

5.3 Prague Classification (Reporting Standard)

The Prague C & M Criteria provide standardized reporting of Barrett's extent: [9]

C value (Circumferential extent):

• Length of circumferential Barrett's segment above the GOJ (cm)

M value (Maximum extent):

• Maximal extent of Barrett's tongues above the GOJ (cm)

Examples:

• C3M5: 3 cm circumferential segment, with tongues extending to 5 cm
• C0M2: No circumferential segment, tongues up to 2 cm

Classification by length:

• Short-segment Barrett's (SSBO): less than 3 cm (C value less than 3)
• Long-segment Barrett's (LSBO): ≥3 cm (C value ≥3)

Clinical relevance:

• Longer segments have higher malignant potential [6]
• Determines surveillance intervals [3]

5.4 Biopsy Protocol (Seattle Protocol)

Purpose: Maximize detection of dysplasia and confirm intestinal metaplasia. [3]

Standard protocol:

1. Four-quadrant biopsies every 2 cm throughout Barrett's segment
2. Targeted biopsies of any visible lesions (nodules, ulcers, strictures)
3. Separate containers for each level (to guide treatment if dysplasia found)

Minimum biopsies:

• Short-segment (less than 3 cm): ≥8 biopsies
• Long-segment (≥3 cm): ≥8 biopsies plus additional quadrantic biopsies every 2 cm

Enhanced detection:

• Chromoendoscopy (acetic acid, Lugol's iodine): Highlights dysplasia
• Narrow-band imaging (NBI): Enhances mucosal/vascular patterns
• Confocal laser endomicroscopy: Real-time histology (specialist centers)

5.5 Histological Diagnosis

Required features for Barrett's: [1]

• Columnar epithelium lining the oesophagus
• Goblet cells (intestinal metaplasia): Mucin-containing cells staining with Alcian blue

Goblet cells are ESSENTIAL for diagnosis (per ACG/BSG guidelines). [1,3]

Grading dysplasia: [6]

Expert pathology review: All dysplasia should be confirmed by two expert GI pathologists due to high inter-observer variability. [3,6]

5.6 Adjunctive Investigations

Indications:

• Assess reflux severity
• Evaluate for complications
• Pre-operative planning

---

6. Surveillance

6.1 Rationale for Surveillance

Goal: Early detection and treatment of dysplasia before progression to invasive adenocarcinoma. [3]

Evidence:

• Surveillance-detected cancers are earlier stage (T1) vs. symptomatic cancers (T3/T4)
• Earlier cancers have better prognosis (5-year survival: T1 > 90% vs. T3 less than 20%) [2]
• Cost-effectiveness remains debated, especially for non-dysplastic Barrett's [3]

6.2 Surveillance Intervals (BSG 2014 / ACG 2022 Guidelines)

Non-dysplastic Barrett's: [1,3]

Dysplastic Barrett's:

Post-ablation surveillance:

• Every 3 months for first year
• Then annually indefinitely [6]

6.3 Who Should Be Surveilled?

Include:

• Histologically confirmed Barrett's oesophagus (intestinal metaplasia) [3]
• Patients fit for endoscopic/surgical intervention if dysplasia detected

Exclude:

• Life expectancy less than 5 years (comorbidities, advanced age)
• Unfit for intervention (severe cardiopulmonary disease)
• Patient preference (after informed discussion of risks/benefits) [3]

Controversial:

• Very short Barrett's (less than 1 cm): Some guidelines suggest discharge after 2 normal surveillances [3]

6.4 Optimizing Surveillance Quality

Best practices: [3]

• High-definition white-light endoscopy (minimum standard)
• Seattle protocol biopsies (four-quadrant every 2 cm)
• Advanced imaging (NBI, chromoendoscopy) to target dysplasia
• Adequate inspection time (minimum 1 minute per cm of Barrett's)
• Document Prague C & M on every endoscopy report

---

7. Management

Management is stratified by dysplasia grade.

┌─────────────────────────────────────────────────────────────────────────────┐
│                  BARRETT'S MANAGEMENT ALGORITHM                             │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │          NON-DYSPLASTIC BARRETT'S OESOPHAGUS                        │   │
│   │  ✓ PPI therapy: Continuous high-dose (symptom control + possible   │   │
│   │    chemoprotection)                                                 │   │
│   │  ✓ Lifestyle modification: Weight loss, avoid late meals, smoking  │   │
│   │    cessation                                                        │   │
│   │  ✓ Surveillance endoscopy: Per guidelines (see above)              │   │
│   │  ✗ Routine ablation: NOT recommended (low cancer risk vs. risks)   │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │          INDEFINITE FOR DYSPLASIA                                   │   │
│   │  • Optimize PPI therapy (high-dose BID × 8-12 weeks)                │   │
│   │  • Treat active inflammation                                        │   │
│   │  • Repeat endoscopy + biopsy in 3-6 months                          │   │
│   │  • Expert pathology review                                          │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │          CONFIRMED LOW-GRADE DYSPLASIA (LGD)                        │   │
│   │  ✓ PREFERRED: Endoscopic ablation (RFA)                            │   │
│   │    - Reduces progression to HGD/cancer by 25% vs. surveillance      │   │
│   │    - Eradicates dysplasia in > 90%                                   │   │
│   │  • ALTERNATIVE: Enhanced surveillance (6-monthly) if patient        │   │
│   │    declines/unfit for ablation                                      │   │
│   │  • Expert pathology confirmation MANDATORY (2 pathologists)         │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                    ↓                                        │
│   ┌─────────────────────────────────────────────────────────────────────┐   │
│   │          CONFIRMED HIGH-GRADE DYSPLASIA (HGD) / EARLY CANCER        │   │
│   │  ✓ Endoscopic therapy (FIRST-LINE):                                │   │
│   │    1. EMR for visible lesions (nodules/ulcers) → Staging + therapy │   │
│   │    2. RFA for flat mucosa → Eradicate residual Barrett's           │   │
│   │  • Outcomes: Complete eradication dysplasia > 90%, complete          │   │
│   │    eradication intestinal metaplasia > 75%                           │   │
│   │  • Surgery (oesophagectomy): Reserved for:                          │   │
│   │    - Submucosal invasion (T1b)                                      │   │
│   │    - Lymphovascular invasion                                        │   │
│   │    - Failed endoscopic therapy                                      │   │
│   │    - Multifocal disease                                             │   │
│   └─────────────────────────────────────────────────────────────────────┘   │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

7.1 Medical Management (All Patients)

Proton Pump Inhibitors (PPIs)

Indications: [7]

• Symptom control of GORD (all Barrett's patients)
• Chemoprevention: Possible reduction in progression to dysplasia/cancer

Dosing:

• Standard dose: Omeprazole 20 mg OD, Lansoprazole 30 mg OD, Esomeprazole 40 mg OD
• High-dose: Double dose BID if refractory symptoms or active inflammation

Evidence for chemoprevention: [7]

• Observational studies suggest PPIs reduce progression risk
• Mechanism: Reduces acid/bile reflux, decreases inflammation, inhibits COX-2
• ACG guideline: Recommends PPI therapy for all Barrett's patients (quality of evidence: moderate) [3]

Side effects (long-term):

• Osteoporosis, fractures (calcium malabsorption)
• C. difficile infection
• Hypomagnesemia
• Vitamin B12 deficiency
• Small intestinal bacterial overgrowth (SIBO)
• Possible increased cardiovascular events (controversial)

Aspirin and NSAIDs (Chemoprevention)

Mechanism: COX-2 inhibition reduces inflammation and cellular proliferation. [7]

Evidence:

• Observational studies: Aspirin use associated with 30-50% reduction in progression to cancer [7]
• Limitations: Increased risk of GI bleeding, cardiovascular events in some populations

Current recommendation: [3,7]

• NOT routinely recommended for Barrett's chemoprevention alone
• Consider in patients with other indications (cardiovascular disease prevention)
• Ongoing trials (AspECT trial) investigating aspirin + PPI vs. PPI alone

Lifestyle Modification

Recommendations: [5]

• Weight loss: Target BMI less than 25 (especially reduce central obesity)
• Dietary: Avoid large meals, fatty foods, chocolate, caffeine, alcohol
• Behavioral: Elevate head of bed, avoid eating 3 hours before bed, left lateral sleeping position
• Smoking cessation: Reduces reflux and cancer risk

7.2 Endoscopic Therapy for Dysplasia

Revolutionized management of dysplastic Barrett's and early cancer. Now first-line for HGD/intramucosal cancer. [6]

Endoscopic Mucosal Resection (EMR)

Technique:

• Lift and cut: Submucosal injection → snare resection of visible lesions
• Indications: [6]
  • Visible nodules/lesions in Barrett's segment
  • "Staging: Depth of invasion (T1a vs. T1b)"
  • "Therapeutic: Complete excision of dysplasia/early cancer"

Outcomes:

• Curative for intramucosal cancer (T1a) in 80-90% [6]
• Complications: Bleeding (2-5%), stricture (10-15%), perforation (less than 1%)

Histology dictates further management:

• T1a (mucosal): Cure if R0 resection (clear margins) → Complete eradication with RFA
• T1b (submucosal): High risk lymph node metastasis (15-20%) → Consider surgery [6]

Radiofrequency Ablation (RFA)

Technique:

• Thermal destruction of Barrett's epithelium using radiofrequency energy (balloon or paddle catheter)
• Depth: Controlled ablation of mucosa (~500 μm), sparing submucosa

Indications: [6,10]

• Flat high-grade dysplasia (after EMR of nodules)
• Flat low-grade dysplasia (increasingly preferred over surveillance)
• Residual non-dysplastic Barrett's after EMR (to prevent recurrence)

Outcomes: [10]

• Complete eradication of dysplasia (CE-D): 90-95% in HGD
• Complete eradication of intestinal metaplasia (CE-IM): 75-85%
• Durability: 80-85% remain disease-free at 5 years (with PPI therapy)

Complications:

• Stricture: 5-10% (higher if EMR + RFA)
• Bleeding: Rare (less than 1%)
• Chest pain: Common (transient)
• Buried Barrett's: Residual glands beneath neo-squamous epithelium (5-15%) – clinical significance uncertain

Post-ablation surveillance:

• Endoscopy every 3 months × 1 year, then annually indefinitely
• Lifelong PPI therapy mandatory [6]

Cryotherapy

Alternative ablative technique using liquid nitrogen or carbon dioxide spray.

Indications:

• Second-line if RFA fails/not tolerated
• Large areas of dysplasia

Outcomes: Comparable to RFA but less data; not widely available. [6]

7.3 Surgical Management

Indications for Oesophagectomy

Now reserved for: [6]

• Submucosal invasion (T1b or deeper) on EMR histology
• Lymphovascular invasion
• Poor differentiation (high risk nodal metastases)
• Failed endoscopic therapy (persistent/recurrent HGD despite ablation)
• Multifocal disease unsuitable for endoscopic resection

NOT indicated for:

• High-grade dysplasia (endoscopic therapy first-line) [6]
• Non-dysplastic Barrett's (no role)

Surgical Options

Oesophagectomy:

• Ivor-Lewis (right thoracotomy + laparotomy): Most common
• Transhiatal (abdominal + cervical): Avoids thoracotomy
• Minimally invasive oesophagectomy (MIO): Laparoscopic/thoracoscopic

Mortality: 2-5% in high-volume centers (> 10% in low-volume centers). [6]

Morbidity: Anastomotic leak (10-15%), stricture (20-30%), respiratory complications, chyle leak, recurrent laryngeal nerve injury.

Anti-reflux surgery (fundoplication):

• Does NOT prevent progression of Barrett's to cancer [5]
• Indications: Severe reflux symptoms despite PPI, patient preference to avoid lifelong PPI
• No role for cancer prevention in Barrett's patients [3,5]

---

8. Prognosis

8.1 Non-Dysplastic Barrett's

• Life expectancy: Near-normal (similar to general population) [2]
• Cancer risk: Low (0.2-0.5% per year) [6]
• Surveillance: Detects dysplasia early, enabling curative endoscopic therapy

8.2 Dysplastic Barrett's

Low-grade dysplasia:

• Progression to HGD/cancer: 0.5-1% per year (surveillance) [6]
• After RFA: > 90% eradication, 75-80% remain disease-free at 5 years [10]

High-grade dysplasia:

• Untreated: 5-7% per year progress to invasive cancer [6]
• After endoscopic therapy (EMR + RFA):
  • "Complete response: 90-95% [6]"
  • "5-year survival: > 95% (equivalent to surgery, without operative mortality) [6]"

8.3 Oesophageal Adenocarcinoma (Invasive)

Stage-dependent:

• T1a (intramucosal): 5-year survival > 90% (endoscopic therapy) [6]
• T1b (submucosal): 5-year survival 60-80% (surgery ± chemotherapy)
• T2-T3 (locally advanced): 5-year survival 20-40% (multimodal therapy)
• T4/M1 (advanced/metastatic): 5-year survival less than 10% [2]

Key message: Early detection through surveillance transforms prognosis.

---

9. Screening for Barrett's Oesophagus

9.1 Population Screening: NOT Recommended

Rationale: [3,11]

• Low prevalence in general population (1.6%)
• Low cancer risk in non-dysplastic Barrett's (0.2-0.5%/year)
• Cost-effectiveness: Not favorable for mass screening
• Resource burden: Insufficient endoscopy capacity

9.2 Targeted Screening (Case-Finding)

Consider screening in: [3,11]

High-risk individuals:

• Age > 50 years + chronic GORD (> 5-10 years) + ≥3 of:
  • Male gender
  • White ethnicity
  • "Central obesity (waist circumference: M > 102 cm, F > 88 cm)"
  • Smoking history
  • First-degree relative with Barrett's/OAC

ACG 2022 guideline: [3]

• Screen men with chronic (> 5 years) and/or frequent (weekly+) GORD symptoms plus ≥2 risk factors

BSG 2014 guideline: [1]

• Consider screening in patients with multiple risk factors; no universal recommendation

9.3 Novel Screening Technologies

Limitations of endoscopy:

• Invasive, expensive, sedation required, limited capacity

Emerging non-endoscopic methods: [11]

• Cytosponge™: Swallowable sponge capsule → samples distal oesophagus → immunocytochemistry for TFF3 (Barrett's marker)

  • "Sensitivity: 80-90% for Barrett's detection"
  • "Acceptability: 85-90% patients (vs. 60% for endoscopy in community)"
  • Cost-effective for screening high-risk populations
  • Currently used in NHS Barrett's screening trials (BEST3)

• Capsule endoscopy: Limited by inability to biopsy

• Volatile organic compounds (breath test): Experimental

---

10. Special Considerations

10.1 Barrett's in Women

• Lower prevalence than men (2-3 fold) [4]
• Lower cancer risk: Unclear if independent of Barrett's length/age
• Screening: Same risk-factor approach; consider in high-risk women

10.2 Barrett's in Younger Patients (less than 50 years)

• Uncommon but increasingly recognized
• Longer lifetime cancer exposure: May warrant more intensive surveillance
• Obesity-driven: Rising incidence parallels obesity epidemic [5]

10.3 Ethnic Differences

Barrett's and OAC are diseases predominantly of white populations. [4]

• Asian populations: 3-4 fold lower prevalence
• Possible mechanisms: Genetic factors, lower obesity rates, dietary differences, H. pylori prevalence
• Clinical implication: Lower threshold for screening in white patients with GORD

10.4 Genetic Susceptibility

• Familial clustering: 3-fold increased risk in first-degree relatives [5]
• Heritability: Estimated 35% (twin studies)
• Candidate genes: Unclear; genome-wide association studies (GWAS) identify susceptibility loci (e.g., FOXF1, BARX1)
• Clinical implication: Family history should inform screening decisions

10.5 Barrett's After Oesophagectomy

• Recurrence: Barrett's can develop in residual oesophagus or gastric conduit (rare)
• Surveillance: Not routinely recommended unless symptomatic

---

11. Controversies and Evolving Areas

11.1 Biomarkers for Risk Stratification

Goal: Identify Barrett's patients at highest cancer risk to personalize surveillance intensity.

Promising biomarkers: [12]

• p53 immunohistochemistry: Abnormal staining predicts progression
• Aneuploidy/tetraploidy (flow cytometry): High-risk marker
• Methylation panels: Epigenetic changes predict neoplastic progression
• Tissue biomarker panels (TissueCypher™): Combines multiple markers; commercially available in USA

Limitations: Not yet incorporated into international guidelines; validation ongoing.

11.2 Non-Dysplastic Barrett's: To Surveil or Not?

Controversy: Given low cancer risk (0.2-0.5%/year), is surveillance cost-effective?

Arguments FOR surveillance: [3]

• Detects dysplasia early (curative endoscopic therapy)
• Surveillance-detected cancers have better outcomes

Arguments AGAINST surveillance:

• Low absolute cancer risk (most never develop cancer)
• High cost per cancer detected
• Anxiety, complications from repeated endoscopy

Current consensus: Surveillance recommended if patient fit and willing (BSG, ACG guidelines), but individualize based on comorbidities, life expectancy, patient preference. [1,3]

11.3 Role of Ablation in Non-Dysplastic Barrett's

Question: Should we ablate all Barrett's (eradicate pre-cancer entirely)?

Evidence:

• RFA reduces Barrett's extent by 75-90% [10]
• Prevents progression? Unclear – non-dysplastic Barrett's has low cancer risk baseline

Trials:

• SURF trial: RFA vs. surveillance in non-dysplastic Barrett's → No cancer benefit at 3 years (very low event rate in both groups)

Current recommendation: [3,6]

• NOT recommended for routine ablation of non-dysplastic Barrett's
• Reserve for dysplastic Barrett's or research protocols

11.4 Duration of Surveillance After Successful Ablation

Question: After complete eradication (CE-IM), can surveillance stop?

Evidence:

• Recurrence: 10-20% develop recurrent intestinal metaplasia over 5 years [10]
• Cancer risk post-ablation: Very low, but not zero

Current recommendation: [6]

• Lifelong annual surveillance after successful ablation
• Lifelong PPI therapy essential (prevent recurrence)

---

12. Key Clinical Pearls

For Examinations (MRCP, FRCS, Viva Scenarios)

Exam Fact 1: Definition and Diagnosis

Barrett's oesophagus requires:

1. Endoscopic evidence of columnar-lined oesophagus (salmon-pink mucosa above GOJ)
2. Histological confirmation of intestinal metaplasia (goblet cells)

Key point: Columnar epithelium without goblet cells is NOT Barrett's (per Western guidelines). [1,3]

Exam Fact 2: Prague Criteria

C & M values standardize reporting:

• C (Circumferential): Continuous ring of Barrett's above GOJ
• M (Maximum): Maximal extent of Barrett's tongues above GOJ

Example: C3M5 = 3 cm circumferential, tongues to 5 cm

Clinical relevance: Longer segments (≥3 cm) → more frequent surveillance (every 2-3 years vs. 3-5 years). [3]

Exam Fact 3: Dysplasia Grading Determines Management

• Non-dysplastic: PPI + surveillance
• LGD: RFA preferred (or 6-monthly surveillance if patient declines)
• HGD: Mandatory endoscopic therapy (EMR for nodules, RFA for flat areas)

Never say: "Oesophagectomy for HGD" – Endoscopic therapy is first-line! [6]

Exam Fact 4: Annual Cancer Risk

• Non-dysplastic: 0.2-0.5% per year [6]
• LGD: 0.5-1% per year
• HGD: 5-7% per year (untreated)

Key message: Surveillance detects dysplasia early → endoscopic therapy prevents cancer.

Exam Fact 5: RFA Outcomes

• Complete eradication dysplasia (CE-D): > 90% [10]
• Complete eradication intestinal metaplasia (CE-IM): 75-85%
• Durability: 80% disease-free at 5 years (with PPI adherence)

Post-ablation: Lifelong PPI + annual surveillance mandatory. [6]

Exam Fact 6: When to Refer for Surgery

Indications for oesophagectomy: [6]

• Submucosal invasion (T1b) on EMR histology
• Lymphovascular invasion
• Failed endoscopic therapy (persistent HGD despite ablation)

NOT indicated: HGD alone, non-dysplastic Barrett's

Exam Fact 7: Chemoprevention

• PPIs: Recommended for all Barrett's (symptom control + possible chemoprotection) [3,7]
• Aspirin: NOT routinely recommended for Barrett's alone (GI bleeding risk vs. uncertain benefit) [3,7]

Common Viva Scenarios

Scenario 1: Incidental Finding

"60-year-old man with 15-year history of heartburn. OGD shows C4M6 salmon-pink mucosa. What do you do?"

Answer:

1. Biopsy: Seattle protocol (four-quadrant biopsies every 2 cm) to confirm intestinal metaplasia and assess for dysplasia
2. Explain diagnosis: Barrett's oesophagus, pre-cancerous condition, low cancer risk (~0.3%/year), requires surveillance
3. Manage:
   • PPI therapy: High-dose (e.g., omeprazole 20-40 mg OD) for symptom control
   • Lifestyle advice: Weight loss, smoking cessation, dietary modification
4. Surveillance plan:
   • If no dysplasia on histology: Surveillance endoscopy every 2-3 years (long-segment > 3 cm)
   • If dysplasia detected: Refer to specialist center

Scenario 2: High-Grade Dysplasia

"Surveillance endoscopy in Barrett's patient shows focal nodule. Biopsy confirms high-grade dysplasia. Management?"

Answer:

1. Confirm diagnosis: Expert pathology review (two GI pathologists)
2. Staging: Endoscopic mucosal resection (EMR) of nodule → Assess depth of invasion (T1a vs. T1b)
3. Endoscopic therapy (if T1a or HGD):
   • EMR for visible lesion (therapeutic + diagnostic)
   • RFA for residual flat Barrett's (eradicate remaining at-risk mucosa)
4. Outcomes: > 90% complete eradication dysplasia; 5-year survival > 95% [6]
5. Surgery: Only if submucosal invasion (T1b) or lymphovascular invasion on EMR histology

Scenario 3: Screening Question

"Should we screen all patients with GORD for Barrett's oesophagus?"

Answer: No – population screening not recommended. [3,11]

Rationale:

• Low prevalence (1-2% general population)
• Low cancer risk (0.2-0.5%/year in non-dysplastic Barrett's)
• Not cost-effective
• Resource constraints (endoscopy capacity)

Targeted screening (case-finding):

• Consider in high-risk patients: Age > 50, chronic GORD (> 5 years), plus ≥2-3 risk factors:
  • Male, white ethnicity, central obesity, smoking, family history Barrett's/OAC [3,11]

Emerging: Cytosponge™ (non-endoscopic cell sampling) may enable cost-effective screening in future. [11]

---

13. Patient Explanation (Layperson Level)

What is Barrett's Oesophagus?

"Barrett's oesophagus is a condition where the lining of your food pipe (gullet) has changed. Normally, the gullet has a pale lining, but in Barrett's, the lower part develops a reddish lining similar to your stomach. This happens because of acid reflux – stomach acid washing up into the gullet over many years causes the gullet lining to adapt."

Is it cancer?

"No, Barrett's is not cancer. However, it is considered a 'pre-cancerous' condition, meaning there is a small risk it could develop into cancer in the future. The risk is actually quite low – about 3-5 people out of every 1,000 with Barrett's will develop cancer each year."

Why did I get it?

"Barrett's develops because of long-term acid reflux (heartburn). Other factors that increase risk include being male, overweight, over 50, white ethnicity, and smoking. It's not something you did wrong – it's related to how your body responds to acid reflux."

What happens now?

"We will monitor your Barrett's with regular camera tests (endoscopies) – usually every 2-5 years depending on the size of the affected area. During these tests, we take small samples (biopsies) to check for any early changes. We'll also give you tablets to reduce stomach acid (PPIs) to protect your gullet and reduce symptoms."

Can it be cured?

"For most people with Barrett's, the goal is monitoring, not curing, because the risk of cancer is low. If we detect more serious changes (called dysplasia), we can treat the affected area using heat energy through the camera (called ablation) to remove it. This is very effective and avoids the need for major surgery."

What should I look out for?

"Contact your doctor urgently if you develop:

• Difficulty swallowing (food getting stuck)
• Unintentional weight loss
• Vomiting blood or black stools
• Severe new pain when swallowing

These could be warning signs that need urgent investigation."

---

14. Evidence & Guidelines

14.1 Major International Guidelines

14.2 Evidence-Based Recommendations with Levels

---

15. References

1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42. doi:10.1136/gutjnl-2013-305372

2. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014;371(9):836-845. doi:10.1056/NEJMra1314704

3. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022;117(4):559-587. doi:10.14309/ajg.0000000000001680

4. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392-1399. doi:10.1053/j.gastro.2006.08.032

5. Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149(2):302-317. doi:10.1053/j.gastro.2015.04.053

6. Cotton CC, Wolf WA, Overholt BF, et al. Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. Gastroenterology. 2017;153(3):681-688. doi:10.1053/j.gastro.2017.05.044

7. Bresalier RS, Cello JP, Genta RM, et al. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci. 2018;63(8):2035-2041. doi:10.1007/s10620-018-5148-6

8. Rhee H, Farris AB 3rd, McDonald OG. Cellular Origins of Barrett's Esophagus: the Search Continues. Curr Gastroenterol Rep. 2018;20(10):50. doi:10.1007/s11894-018-0655-0

9. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392-1399. doi:10.1053/j.gastro.2006.08.032

10. Watts AE, Haidry R. Radiofrequency Ablation of Barrett's Esophagus: Have We Gone Too Far, or Not Far Enough? Curr Gastroenterol Rep. 2020;22(6):28. doi:10.1007/s11894-020-00762-w

11. di Pietro M, Fitzgerald RC. Screening for Barrett's Esophagus. Gastroenterology. 2015;148(5):912-923. doi:10.1053/j.gastro.2015.02.012

12. Sharma P, Katzka DA, Gupta N, et al. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015;149(6):1599-1606. doi:10.1053/j.gastro.2015.08.007

13. Fabian T. Epidemiology of Barrett's Esophagus and Esophageal Carcinoma. Surg Clin North Am. 2021;101(3):381-389. doi:10.1016/j.suc.2021.03.001

14. Sharma P. Barrett Esophagus: A Review. JAMA. 2022;328(7):663-671. doi:10.1001/jama.2022.13298

15. Mukaisho KI, Kanai S, Kushima R, et al. Barretts's carcinogenesis. Pathol Int. 2019;69(6):319-330. doi:10.1111/pin.12804

16. Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024;385:e070350. doi:10.1136/bmj-2022-070350

17. Dunbar KB, Spechler SJ. The Effect of Proton Pump Inhibitors on Barrett's Esophagus. Gastroenterol Clin North Am. 2015;44(2):415-424. doi:10.1016/j.gtc.2015.02.013

18. Ko MT, Huang CH, Chen CY, et al. Chemoprevention of Barrett's Esophagus: a Systematic Review and Comprehensive Assessment of Bias. Dis Esophagus. 2025;38(1):doae096. doi:10.1093/dote/doae096

19. Provoost N, Snijders L, Siersema PD, et al. Barrett's esophagus screening: Current modalities, risk-based approaches, and future perspectives. Best Pract Res Clin Gastroenterol. 2025;73:101949. doi:10.1016/j.bpg.2024.101949

20. Zakko L, Lutzke L, Wang KK. Screening for Barrett's esophagus. Minerva Med. 2017;108(1):8-21. doi:10.23736/S0026-4806.16.04872-5

---

Document Information:

• Version: 2.0 (Enhanced)
• Last Updated: 2026-01-06
• Author: MedVellum Content Team
• Evidence Base: PubMed systematic search (2014-2025)
• Next Review: 2027-01-06

---

Learning Objectives:

After studying this topic, you should be able to:

1. Define Barrett's oesophagus and explain its pathophysiology
2. Identify patients at high risk for Barrett's and oesophageal adenocarcinoma
3. Describe the diagnostic criteria including Prague classification and histological features
4. Apply appropriate surveillance protocols based on segment length and dysplasia grade
5. Select evidence-based management strategies for non-dysplastic and dysplastic Barrett's
6. Explain the role and outcomes of endoscopic therapy (EMR and RFA)
7. Counsel patients about cancer risk, surveillance rationale, and treatment options